Sirtex Medical Overview
Company Headquarters: Massachusetts, US
Founded: 1997
Workforce: >261
Company Working: Sirtex Medical is a global healthcare company with offices in the US, Australia, Germany, and Singapore. The company has manufacturing facilities in the US and Germany. As of June 2018, Sirtex Medical Systems operates as a subsidiary of CDH Investments (China). The company’s lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 50 countries. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union, Argentina, Brazil, Canada and several countries in Asia, such as India and Singapore.
Strategy
Sirtex Medical aims to develop high-quality and cost-effective products to strengthen its market position in the embolization particle market. It focuses on tapping major markets such as the US, and European countries to increase its market share in the global market. Additionally, the company also focuses on strategic collaborations with academic and government institutions.
